Effects of silodosin on lower urinary tract symptoms in patients with benign prostatic hyperplasia: Evaluation by frequency/volume chart

LUTS: Lower Urinary Tract Symptoms

Volumn 2, Issue 1, 2010, Pages 31-36

  Watanabe, Miho ^a   Yamanishi, Tomonori ^a   Mizuno, Tomoya ^a   Tatsumiya, Katsuhisa ^a   Masuda, Akinori ^a   Honda, Mikihiko ^a   Uchiyama, Tomoyuuki ^b   Sakakibara, Ryuji ^c   Yoshida, Ken Ichiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Alpha blocker; Benign prostate hyperplasia; Frequency volume chart; Lower urinary tract symptoms; Silodosin

Indexed keywords

NAFTOPIDIL; SILODOSIN; TAMSULOSIN; URAPIDIL;

AGED; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EJACULATION DISORDER; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOOSE FECES; LOWER URINARY TRACT SYMPTOM; MALE; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SIDE EFFECT; SKIN PRURITUS; THIRST; URINARY FREQUENCY; URINE FLOW RATE; URINE VOLUME; UROFLOWMETRY;

EID: 79951752848     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2010.00059.x     Document Type: Article

References (33)

1. 1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: 193-9.
2. Speakman MJ. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): more than treating symptoms? Eur Urol Suppl 2008; 7: 680-9.
3. Berry SJ, Coffey DS, Walsh PC, Ewing LJ. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
4. Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-3.
5. Djavan B, Chapple C, Marberger M et al. State of the art on the efficacy and tolerability of alpha-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-8.
6. Yamanishi T, Yasuda K, Kamai T et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (evipro-stat) in the treatment of benign prostatic hyperplasia. Int J Urol 2004; 11: 501-9.
7. Yamanishi T, Tatsumiya K, Furuya N et al. Long-term efficacy of tamsulosin in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in reallife practice. UIJ 2009; 2: DOI: 10.3834/uij.1944-5784.2009.02.01
8. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alphaA1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546-51.
9. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha (1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634-40.
10. Kawabe K, Yoshida M, Homma Y, for the Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, doubleblind study in Japanese men. BJU Int 2006; 98: 1019-24.
11. Takao T, Tsujimura A, Kiuchi H et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol, 2008; 15: 992-6.
12. 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. DOI: 10.1002/nau.20802.
13. 1-adrenoceptors and native tissues. Mol Pharmacol 1995; 48: 250-8.
14. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence society. Neurourol Urodyn 2002; 21: 167-78.
15. 1-Adrenergic receptor subtypes in human detrusor. J Urol 1998; 160: 937-43.
16. 1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002; 167: 1513-21.
17. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003; 170: 649-53.
18. Smith MS, Schambra UB, Wilson KH et al. Alpha1-adrenergic receptors in human spinal cord: specific localized expression on mRNA encoding α1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 1999; 63: 254-61.
19. Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and - 1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002; 328: 74-6.
20. Yoshiyama M, DeGroat WC. Role of spinal α1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol 2001; 280: R1414-9.
21. Kira S, Yamagishi T, Inuzuka H et al. Silodosin, a novel alpha 1A AR-super selective antagonist, rapidly improves bothersome nocturia in patients who are resistant to tamsulosin/naftopidil. J Urol 2009; 181(Suppl): 695, Abstract.
22. Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 2006; 13: 15-20.
23. Nishino Y, Masue T, Miwa K. Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized cross over study. BJU Int 2006; 97: 747-51.
24. Ikemoto I, Kiyota H, Ohishi Y. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol 2003; 10: 587-594.
25. Oh-oka H. Effect of naftopidil on nocturia after failure of tamsulosin. Urology 2008; 72: 1051-5.
26. Ukimura O, Kanazawa M, Fujihara A, Kamoi K, Okihara K, Miki T, Kyoto Prefectural University of Medicine Benign Prostatic Hypertrophy Research Group. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Int J Urol 2008; 15: 1049-54.
27. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Ori-gasa H, Tokai Urological Clinical Trial Group. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005; 96: 581-6.
28. Momose H, Hosokawa Y, Kishino T, Ono T, Oyama N. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs Today 2007; 43(Suppl A): 1-10.
29. Tatemichi S, Akiyama K, Kobayashi M, Yamazaki Y, Yokoyama O, Uruno T. A selective α1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006; 176: 1236-41.
30. Matsukawa Y, Hattori R, Komatsu T et al. Early efficacy of silodosin on storage and voiding function in patients with benign prostatic hyperplasia, based on pressure-flow study. J Urol 2009; 181(Suppl 4): 694, Abstract.
31. Pinggera GM, Mitterberger M, Pallwein L et al. Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2007; 101: 319-24.
32. Rudner XL, Berkowitz DE, Booth JV et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 2336-43.
33. Yamanishi T, Mizuno T, Kamai T, Yoshida K, Sakakibara R, Uchiyama T. Management of benign prostatic hyperplasia with silodosin. Open Access J Urol 2009; 1: 1-7.